CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

NCT03998163 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

222

Enrollment

INDUSTRY

Sponsor class

Conditions

Uremic Pruritus

Interventions

DRUG: CR845 0.5 mcg/kg

Sponsor

Cara Therapeutics, Inc.